Role of β2 adrenergic receptors in human atherosclerotic coronary arteries

被引:61
作者
Barbato, E
Piscione, F
Bartunek, J
Galasso, G
Cirillo, P
De Luca, G
Iaccarino, G
De Bruyne, B
Chiariello, M
Wijns, W
机构
[1] Univ Naples Federico II, Div Cardiol, I-80131 Naples, Italy
[2] Univ Naples Federico II, Div Internal Med, I-80131 Naples, Italy
[3] Ctr OLVZ, Ctr Cardiovasc, Aalst, Belgium
关键词
receptors; adrenergic; alpha; beta; atherosclerosis; endothelium; acetylcholine;
D O I
10.1161/01.CIR.0000153270.25541.72
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background - Adrenergic regulation of coronary vasomotion is balanced between alpha(1)-adrenergic-mediated (alpha(1)-AR) constriction and beta(2)-adrenergic-mediated (beta(2)-AR) relaxation. This study aimed at assessing the role of beta(2)-ARs in normal, mildly atherosclerotic, and stenotic human coronary arteries. Methods and Results - During intracoronary (IC) infusion of increasing doses of the beta(2)-AR agonist salbutamol (0.15, 0.3, and 0.6 mug/min) and the endothelial vasodilator acetylcholine ( 1, 3, and 10 mug/min), we measured ( 1) changes in lumen diameter (LD) by quantitative coronary angiography in 34 normal, 55 mildly atherosclerotic, and 42 stenotic coronary artery segments and ( 2) changes in average peak velocity (APV) and coronary blood flow (CBF) with the use of Doppler flow wire in 11 normal, 10 mildly atherosclerotic, and 11 stenotic coronary arteries. In 6 of 11 stenotic coronary arteries, the protocol was repeated after an IC bolus (12 mug/kg) of the alpha-adrenergic blocker phentolamine. In 6 of 11 normal coronary arteries, the protocol was repeated after an IC infusion (60 mumol/min) of N-G-monomethyl-L-arginine (L-NMMA), a nitric oxide inhibitor. Neither salbutamol IC infusion nor acetylcholine significantly changed heart rate or blood pressure, whereas L-NMMA slightly increased blood pressure. In normal coronary arteries, salbutamol increased LD (LD max %: 11 +/- 2, P < 0.05), APV (APV max %: 53 +/- 17, P < 0.05), and CBF (CBF max %: 57 +/- 17, P < 0.05), whereas L-NMMA caused a blunted APV (APV max %: 27 +/- 6, P < 0.05) and CBF ( CBF max %: 29 +/- 6, P < 0.05) response to salbutamol. In mildly atherosclerotic coronary arteries, the salbutamol increase in LD ( LD max %: 10 +/- 2, P < 0.05), APV (APV max %: 33 +/- 12, P < 0.05), and CBF (CBF max %: 37 +/- 12, P < 0.05) was preserved. In stenotic coronary arteries, salbutamol induced a paradoxical reduction in LD (LD max %: - 6 +/- 2, P < 0.05), APV (APV max %: - 15 +/- 9, P < 0.05), and CBF (CBF max %: - 15 +/- 6, P < 0.05), which was no longer observed after phentolamine. Acetylcholine increased LD (LD max %: 14 +/- 3, P < 0.05), APV (APV max %: 61 +/- 20, P < 0.05), and CBF ( CBF max %: 67 +/- 19, P < 0.05) in normal coronary arteries. In mildly atherosclerotic coronary arteries, acetylcholine induced a significant reduction in LD ( LD max %: - 15 +/- 2, P < 0.05) and no changes in APV ( APV max %: - 6 +/- 13, P = NS) and CBF ( CBF max %: - 10 +/- 13, P = NS). In stenotic coronary arteries, acetylcholine significantly reduced LD ( LD max %: - 15 +/- 3, P < 0.05), APV (APV max %: - 15 +/- 9, P < 0.05), and CBF (CBF max %: - 15 +/- 6, P < 0.05). Conclusions - In severely atherosclerotic coronary arteries, beta(2)-adrenergic vasodilatation is impaired, and this might contribute to alter the vasomotor balance, further precipitating myocardial ischemia during sympathetic activation.
引用
收藏
页码:288 / 294
页数:7
相关论文
共 27 条
[1]   Validation of coronary flow reserve measurements by thermodilution in clinical practice [J].
Barbato, E ;
Aarnoudse, W ;
Aengevaeren, WR ;
Werner, G ;
Klauss, V ;
Bojara, W ;
Herzfeld, I ;
Oldroyd, KG ;
Pijls, NHJ ;
De Bruyne, B .
EUROPEAN HEART JOURNAL, 2004, 25 (03) :219-223
[2]   Effects of intravenous dobutamine on coronary vasomotion in humans [J].
Barbato, E ;
Bartunek, J ;
Wyffels, E ;
Wijns, W ;
Heyndrickx, GR ;
De Bruyne, B .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 42 (09) :1596-1601
[3]   ROLE OF BETA-ADRENOCEPTORS IN CORONARY BLOOD-FLOW DISTRIBUTION IN NORMAL AND ISCHEMIC CANINE MYOCARDIUM [J].
BERDEAUX, A ;
GARNIER, M ;
BOISSIER, JR ;
GIUDICELLI, JF .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1979, 53 (03) :261-271
[4]   EFFECT OF INTRAVENOUS PROPRANOLOL ON CORONARY VASOMOTION AT REST AND DURING DYNAMIC EXERCISE IN PATIENTS WITH CORONARY-ARTERY DISEASE [J].
BORTONE, AS ;
HESS, OM ;
GAGLIONE, A ;
SUTER, T ;
NONOGI, H ;
GRIMM, J ;
KRAYENBUEHL, HP .
CIRCULATION, 1990, 81 (04) :1225-1235
[5]   PRESYNAPTIC EFFECTS OF EPINEPHRINE ON NOREPINEPHRINE RELEASE FROM CARDIAC SYMPATHETIC-NERVES IN DOGS [J].
BOUDREAU, G ;
PERONNET, F ;
DECHAMPLAIN, J ;
NADEAU, R .
AMERICAN JOURNAL OF PHYSIOLOGY, 1993, 265 (01) :H205-H211
[6]   RESPONSES OF THE RABBIT EPICARDIAL CORONARY-ARTERY TO ACETYLCHOLINE AND ADRENOCEPTOR AGONISTS [J].
CORR, L ;
BURNSTOCK, G ;
POOLEWILSON, P .
CARDIOVASCULAR RESEARCH, 1991, 25 (03) :256-262
[7]   BETA-ADRENOCEPTOR SUBTYPES IN HUMAN CORONARY-ARTERY - DESENSITIZATION OF BETA(2)-ADRENERGIC VASORELAXATION BY CHRONIC BETA(1)-ADRENERGIC STIMULATION IN-VITRO [J].
FERRO, A ;
KAUMANN, AJ ;
BROWN, MJ .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1995, 25 (01) :134-141
[8]   IS THERE CORONARY VASOCONSTRICTION AFTER INTRACORONARY BETA-ADRENERGIC-BLOCKADE IN PATIENTS WITH CORONARY-ARTERY DISEASE [J].
GAGLIONE, A ;
HESS, OM ;
CORIN, WJ ;
RITTER, M ;
GRIMM, J ;
KRAYENBUEHL, HP .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1987, 10 (02) :299-310
[9]   ENDOTHELIAL MODULATION OF BETA-ADRENERGIC DILATION OF LARGE CORONARY-ARTERIES IN CONSCIOUS DOGS [J].
GHALEH, B ;
BEA, ML ;
DUBOISRANDE, JL ;
GIUDICELLI, JF ;
HITTINGER, L ;
BERDEAUX, A .
CIRCULATION, 1995, 92 (09) :2627-2635
[10]   α-adrenergic blockade improves recovery of myocardial perfusion and function after coronary stenting in patients with acute myocardial infarction [J].
Gregorini, L ;
Marco, J ;
Kozàkovà, M ;
Palombo, C ;
Anguissola, GB ;
Marco, I ;
Bernies, M ;
Cassagneau, B ;
Distante, A ;
Bossi, IM ;
Fajadet, J ;
Heusch, G .
CIRCULATION, 1999, 99 (04) :482-490